An article in Barron's today points out that last week that the biopharmaceutical company had a nine day winning streak end but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and Biogen Idec (BIIB).
Analysts continue to praise Gilead, Barron's said, this week following last week's big earnings beat which helped. Sovaldi success is cited as a significant reason.
A Barron's column over the weekend considered whether Gilead was "really a value stock." The conclusion: "It's more likely a growth-at-a-reasonable-price, or GARP, play."
TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results."